<DOC>
	<DOCNO>NCT02835690</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics ( PK ) efficacy three dos pembrolizumab ( MK-3475 ) adult Chinese participant locally advance metastatic non-small-cell lung cancer ( NSCLC ) . Cycle 1 28 day long ; subsequent cycle 21 day long .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Efficacy Pembrolizumab ( MK-3475 ) Chinese Participants With Non-Small-Cell Lung Cancer ( MK-3475-032/KEYNOTE-032 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Is Chinese race ( i.e. , Chinese descent born China ) Chinese home address . Has life expectancy least 3 month . Has histologically/cytologicallyconfirmed , advance unresectable NSCLC measurable disease base Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) determine site . Has fail establish standard medical anticancer therapy intolerant therapy , opinion investigator consider ineligible form standard therapy medical ground . Has score 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status within 3 day prior first dose study drug . Has adequate organ function . Female participant childbearing potential must willing use adequate method contraception course study 120 day last dose study drug . Male participant childbearing potential must agree use adequate method contraception , start first dose study drug 120 day last dose study drug . Has chemotherapy , radioactive , biological cancer therapy within 4 week prior first dose study therapy pembrolizumab , recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 Grade 1 good AEs due cancer therapeutic administer 4 week earlier . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study drug . Is expect require form antineoplastic therapy study ( include maintenance therapy another agent NSCLC ) . Has medical condition require chronic systemic steroid therapy form immunosuppressive medication . Has know history hematologic malignancy , primary brain tumor sarcoma , another primary solid tumor , unless participant undergone potentially curative therapy evidence disease 5 year . Has know central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Participants previously treat brain metastasis may participate provide stable . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis . Has active autoimmune disease require systemic treatment past 2 year ( i.e. , use disease modify agent , corticosteroid immunosuppressive drug ) . Had prior treatment target PD1 : PDL1 axis cytotoxic Tlymphocyteassociated protein ( CTLA ) , previously randomize pembrolizumab study . Examples agent include ( limited ) : Nivolumab ( BMS936558 , MDX1106 ONO4538 ) ; Pidilizumab ( CT011 ) ; AMP224 ; BMS936559 ( MDX1105 ) ; MPDL3280A ( RG7446 ) ; MEDI4736 . Has active infection require systematic therapy . Is positive Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B C. Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Has receive receive live vaccine within 30 day prior first administration study drug . Is time sign informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) . Is pregnant breastfeeding , expect conceive father child within project duration study , start screen visit ( Visit 1 ) 120 day last dose pembrolizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>